IP Library Granted Patent US 8,927,589
Granted Patent B2
US 8,927,589 · App. 13/834,336 · Granted Jan 6, 2015

3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity

Inventors: Bertrand Leblond (Paris, FR); Eric Beausoleil (Paris, FR); Thierry Taverne (St. Martin Boulogne sur Mer, FR); John E. Donello (Dana Point, CA)
Assignee: Allergan, Inc.
C07D265/30A61K31/40A61K31/4025A61K31/5375C07D213/64C07D295/12C07D319/18A61K31/4409A61K31/4439A61K31/4545A61K31/4709A61K31/496A61K31/5377A61K31/541
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,589
App. No.
13/834,336
Granted
Jan 6, 2015
Kind
B2
Abstract

Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.

Claims (40)

1. A method for treating chronic pain in a mammal, comprising administering to said mammal at least one compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is H or alkyl of 1 to 6 carbons;

R 2 is selected from the group consisting of H, and alkyl of 1 to 6 carbons; or the R 1 and R 2 groups together with the nitrogen atom to which they are shown attached form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally additionally includes one or two heteroatoms independently selected from the group consisting of N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;

R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroalkyl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;

R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;

R 5 and R 6 are independently selected from the group consisting of H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons; or

R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;

said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and

the wavy lines represent bonds of the alpha or beta configuration

with the proviso that the formula excludes the compound of the formula below:

2. A method for treating chronic pain in a mammal, comprising administering to said mammal at least one compound of the formula:

or a pharmaceutically acceptable salt of said compound, wherein:

R 1 and R 2 groups together with the nitrogen atom to which they are shown attached form a saturated 5 or 6 membered ring, said ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;

R 3 is H or alkyl of 1 to 20 carbons; and

R 4 is H or alkyl of 1 to 6 carbons.

3. A method for treating chronic pain in a mammal, comprising administering to said mammal a compound of the formula:

or any other pharmaceutically acceptable salt of

4. A method for treating chronic pain in a mammal, comprising administering to said mammal a compound of the formula:

or a pharmaceutically acceptable salt thereof.

5. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is H or alkyl of 1 to 6 carbons;

R 2 is selected from the group consisting of H, and alkyl of 1 to 6 carbons; or the R 1 and R 2 groups together with the nitrogen atom to which they are shown attached form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally additionally includes one or two heteroatoms independently selected from the group consisting of N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;

R 3 is H, CO—R 7 or CO—O—R 7 where R 7 is H, alkyl of 1 to 20 carbons, cycloalkyl of 3 to 6 carbons, aryl or heteroaryl, aryl-alkyl, aryl(hydroxy)alkyl, heteroaryl-alkyl or heteroalkyl(hydroxy)alkyl where the alkyl moiety has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons;

R 4 is H, alkyl of 1 to 6 carbons, or CO—R 8 where R 8 is alkyl of 1 to 6 carbons;

R 5 and R 6 are independently selected from the group consisting of H, halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 3 carbons; or

R 5 and R 6 together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S;

said carbocyclic or heterocyclic ring jointly formed by R 5 and R 6 being optionally substituted with 1 to 6 R 9 groups where R 9 is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, and

the wavy lines represent bonds of the alpha or beta configuration

with the proviso that the formula excludes the compound of the formula below:

6. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 and R 2 groups together with the nitrogen atom to which they are shown attached form a saturated 5 or 6 membered ring, said ring optionally being substituted with one or two COOH, CH 2 OH, OH, B(OH) 2 , halogen groups, cyano groups or with one or two alkyl groups having 1 to 6 carbons;

R 3 is H or alkyl of 1 to 20 carbons; and

R 4 is H or alkyl of 1 to 6 carbons.

7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the compound has the formula:

8. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the compound has the formula:

9. A pharmaceutical composition comprising at least one compound of claim 5 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

10. A pharmaceutical composition comprising at least one compound of claim 6 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2014
From: BEAUSOLEIL, ERIC; LEBLOND, BERTRAND; TAVERNE, THIERRY; DONELLO, JOHN E.
To: ALLERGAN, INC.
Reel/Frame 034224/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2014
From: ALLERGAN, INC.
To: ALLERGAN, INC.; EXONHIT THERAPEUTICS SA
Reel/Frame 034224/0119 →
Continuity (4)
Continuation 13612260 · Sep 12, 2012
Continuation 11814598
Provisional Application 60647271 · Jan 26, 2005
Related Publication 20130202653A1 · Aug 8, 2013